HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.

Jamie L Felton David D CuthbertsonMegan WarnockKuldeep LohanoFarah Meah John M Wentworth Jay M Sosenko Carmella Evans-Molinanull null

Published in: Diabetologia (2021)

These data suggest that HOMA2-B may have utility as a single-time-point measurement to stratify risk of type 1 diabetes development in Aab+ individuals.

Keyphrases

electronic health record
big data
deep learning